Should psychiatrists follow these leads and use a patient's race or ethnicity to guide treatment decisions? In this article, I will describe the evidence that supports racial profiling in psychiatry and will explore some of the relevant concerns.
A 42-year-old man presents to your clinic asking for help with depression. His complaints are familiar: sadness, some anxiety, loss of appetite, low energy, difficulty in concentrating at work, and inability to sleep despite feeling exhausted. He does not want therapy but would be willing to try a medication. As you reach for your prescription pad, you try to decide which SSRI and what dosage to start with. Should his race or ethnicity affect your decision? Is race a relevant variable for psychopharmacology?These questions have attracted great interest. In a 2002 cover story in the New York Times Magazine, psychiatrist Sally Satel proudly asserted "I Am a Racial Profiling Doctor."1 When she treated African American patients in her Washington, DC, clinic, she started them on lower doses of fluoxetine because, she claimed, "40% of them are slow metabolizers of antidepressants." Citing other examples in medicine, she defended this politically incorrect decision: "When it comes to practicing medicine, stereotyping often works." Racial profiling in medicine received a major boost in June 2005 when the FDA granted BiDil, a fixed-dose combination of isosorbide dinitrate and hydralazine, a specific indication for treating heart failure in patients who identify themselves as black.2
Should psychiatrists follow these leads and use a patient's race or ethnicity to guide treatment decisions? In this article, I will describe the evidence that supports racial profiling in psychiatry and will explore some of the relevant concerns. This is not a systematic review: many good ones have already been published.3-5 Instead, I hope to outline the basic issues and explain why I am not a racial-profiling psychiatrist.
Is race real enough?
Any discussion of racial profiling must start with some basic questions. What exactly is race? What about ethnicity? Are they valid and relevant categories for medical decision making? After all, if we are going to profile, we want to make sure that we are using appropriate variables.
However race is defined, the basic concept in medicine is that different groups of people differ in ways that are biologically significant. This idea is an ancient one. Hippocratic writers taught that bodies adapted themselves to local environments and, as a result, environmental differences became embodied as biologic differences between people from different areas. Wise physicians would have considered these differences in their diagnoses and treatments. As taxonomists began systematic study of biologic diversity in the 18th century, they subjected humans to their classifying efforts.
German naturalist Johann Blumenbach proposed a 5-race classification: Ethiopian, Mongolian, Caucasian, American, and Malay. Later writers, especially in the early 20th century, defended more nuanced divisions, distinguishing English from Irish and Scot, Sicilian from Italian, and so forth. In all these taxonomies, a race was a group of persons that shared both ancestry and superficial distinguishing characteristics (eg, skin color, hair texture, facial structure). Racial distinctions had unchallenged relevance for both social policy and medical practice.
Eagerness to discriminate by race diminished in the mid-20th century in the aftermath of American and Nazi eugenic programs. A consensus emerged, typified by the United Nations Educational, Scientific and Cultural Organization statements on race in 1950 and 1951, arguing that race was artificial and dangerous and should be banned from science and social policy. This idea found support in the work of population geneticists who showed in the 1970s that the amount of variation within groups far exceeded the variation that distinguished between different groups.6,7
Antiracial sentiment reached its zenith in June 2000 at the announcement of the completion of the Human Genome Project. Sharing the stage, Bill Clinton, Craig Venter, and Francis Collins celebrated the finding of human sameness: with all humans sharing 99.9% of their genetic code, race had no basis in genetics.
Race, so entrenched and evocative, could not be dispensed with so easily, however. Throughout the 20th century, researchers had continued to map racial distributions of blood types, drug-metabolizing enzymes, and other genetic and biochemical markers. As soon as the 99.9% overlap was announced, geneticists turned it upside down. Even just a 0.1% variation meant that individuals differ at 3 million base pairs. Within this limited variation lies the secret of all human variability that is of genetic origin, whether for skin color, disease susceptibility, or drug response. Studies of the distribution of genetic variation have supported the validity of racial categories. One analysis of 1056 persons from 52 populations found that it could correctly identify the race and geographic origin of individuals based solely on their genetic markers.8
One of the largest studies of human variation, the International Haplotype Map (HapMap) Project has been interpreted similarly. The HapMap is being created to simplify the search for genetic causes of human disease. By defining which regions of the genome vary, the HapMap will allow researchers to focus their searches on the 0.1% in which variations exist.9,10
The first draft of the HapMap was published in 2005.11 It was based on a carefully selected sample: 90 people from Provo, Utah; 90 from Ibadan, Nigeria; and 90 from Asia (45 each from Tokyo and Beijing). Although the authors did not set out to test the genetic reality of race, they did note that a handful of alleles distinguished these 3 groups. Subsequent clinical studies have used the HapMap to confirm that the self-reported race of research subjects matched their genetic profiles.12 Other work has also demonstrated a close correlation between self-reported race and genetic ancestry. A recent letter in the New England Journal of Medicine reported that persons who self-identified as white generally had greater than 90% European genetic ancestry, while people who self-reported as black had a substantial proportion of African genetic ancestry.13
The implication of this work is that race, as popularly understood, is real and correlates with genetics and ancestry. This seeming clarity came at a useful time. Concerned that minority groups had been underrepresented in clinical research, Congress passed the NIH Revitalization Act of 1993 that mandated the inclusion of diverse populations in clinical research. How has this been implemented? Blumenbach would be proud. The FDA, following the lead of other federal agencies, recognizes 5 races-American Indian or Alaska Native, Asian, black or African American, Native Hawaiian or Other Pacific Islander, and white-and 2 ethnicities-Hispanic or non-Hispanic. Such categorizations, especially ethnicity, leave much to be desired, but they enjoy bureaucratic familiarity and genetic justifications.
Is race relevant forpsychopharmacology?
If these data on the genetics of race are convincing, then the importance of race to psychopharmacology becomes obvious. Researchers have described a series of drug metabolizing enzymes, drug transporters, and drug receptors that affect drug response. A series of liver enzymes, the cytochrome P-450 system, metabolizes a wide variety of psychiatric medications (Table). Many variants exist that produce a range of phenotypes, from poor metabolizers to extensive metabolizers. Poor metabolizers experience higher drug concentrations from a given dose, potentially increasing both efficacy and side effects. These drug metabolizing enzymes can be under tight genetic control, with heritability greater than 90%.14,15 As with many genetic variations, researchers have found that P-450 variants occur at different frequencies in different populations (Table). Racial patterns have also been found in receptors and transporters, especially the serotonin transporter.4,16,17
|P-450 isoenzyme||Common drugs metabolized||Poor metabolizers (%)|
|2C19||Diazepam, tricyclics, citalopram||East Asian (14 - 20) African or African American (18) Caucasian (3 - 7)|
|2D6||Tricyclics, fluoxetine, paroxetine, venlafaxine, sertraline, chlorpromazine, haloperidol, clozapine, risperidone||East Asian (0 - 2) African or African American (0 - 19) Caucasian (3 - 9)|
|3A4||Mirtazapine, sertraline, haloperidol, clozapine, quetiapine, risperidone, ziprasidone, gabapentin, lamotrigine, clonazepam, diazepam, zolpidem||Results inconsistent, but poor metabolizers generally rare (< 1)|
These findings seem to provide a justification for racial profiling in psychiatric prescribing. Asian patients, more likely to be poor metabolizers with 2C19 than whites, should respond to lower doses of diazepam, but might require higher doses of drugs metabolized by 2D6, such as fluoxetine. With drug metabolizing enzymes under genetic control, and modern genomics showing that genetic differences exist between races, it would make sense that drug metabolism will vary from race to race.
The devil is in the details
Given the history of race in America, it is not surprising that concerns about race, genetics, and pharmacology have persisted. When evolutionary biologist Armand Leroi published an editorial in the New York Times defending the importance of race in medicine in March 2005, a collection of prominent scholars wrote critical replies.18 Why does the controversy endure?
First, genomics has not definitively proven that race is a real, stable category. Many of the studies that have found racial differences are, in part, self-fulfilling prophecies. It was not by chance that HapMap researchers first sampled populations that corresponded to Caucasian (Provo), African (Ibadan), and Asian (Tokyo and Beijing). Had they sampled one group of short persons and one group of tall persons, they would also have found genetic differences between the groups. The conclusion should not be that there is a short race and a tall race, an Asian race and a Caucasian race. For example, had the HapMap researchers started in London and sampled one person every 35 miles from there to Tokyo, they would have ended up with a sample of 270 persons that showed a gradient of continuous genetic change, not one that suggested 3 racial clusters.
Similar problems appear with data interpretation. The letter in the New England Journal of Medicine about the correlation of self-reported race and genetics could have been interpreted quite differently. While most white persons (in Cleveland, at least) do seem to be of European descent, some who self-reported as white actually had 70% to 80% African ancestry. Meanwhile, individuals who self-reported as black had indeterminate ancestry, anywhere from less than 10% to more than 90% African ancestry. The data do not indicate that white and black are natural categories. Instead, it appears obvious that "African American" persons have such diverse ancestry that meaningful generalizations cannot be made.
Many other studies have identified limitations of self-reported race. In the 2000 census, more than 7 million people reported multiple races, and more than 800,000 reported being both black and white.19 Another study found that one third changed their self-identified racial and ethnic categories over time.20 Presumably these ambiguities will only increase over time as diverse populations continue to mix.
Another problem is that it remains unclear how best to apply population-based data to individuals. Suppose it is true that 18% of blacks are poor metabolizers with P-450 2C19, while only 3% of whites are. What does this mean for individual black patients? Not that they are poor metabolizers, but that they have an increased risk of being poor metabolizers. An overwhelming majority of both groups (82% of blacks and 97% of whites) would have normal metabolism. All patients should be treated similarly regardless of race.
This has been demonstrated most clearly for antihypertensive medications.21 Many clinical trials have found racial differences in drug response for diuretics, ß-blockers, angiotensin-converting enzyme inhibitors, and many other medications. Captopril, for instance, lowers diastolic blood pressure more in white patients than in black patients (10.7 vs 8.0 mm Hg; P < .001). However, in every study the standard deviation within each racial group far exceeded the differences between the groups. A meta-analysis showed that 80% to 95% of black and white patients had indistinguishable responses to each medication. While racial differences did exist, they were not relevant for most patients. To treat individuals differently because of a slightly different likelihood of being a poor metabolizer would do them a disservice.
Where does this leave clinicians? Many advocates of pharmacogenetics hope to avoid the problems of racial profiling by moving toward personalized medicine. In this ideal future, clinicians will genotype every patient they treat, identifying every relevant drug-metabolizing variant without relying on assumptions about race, ethnicity, or ancestry.22-24 The technology for such personalized medicine is starting to appear: a gene chip for analyzing variants of P-450 2D6 is now available, and others will surely follow.
But even this might not usher in an era of personalized medicine. Many factors, beyond drug metabolizing genotypes, influence patients' responses to medications. Clinicians will need to integrate information about every relevant metabolic pathway with data about drug transporters and receptors. Moreover, a wide range of environmental exposures, including tobacco smoke, charcoal-broiled beef, and many fruits and vegetables can increase the activity of drug-metabolizing enzymes.25
Because of the interplay between genetics and environment, some researchers argue that we should focus not on genotype but on phenotype. Dubbing this new field "pharmacometabonomics," they argue that clinicians should monitor assays of gene expression,26 although this might require retesting patients every time their environmental exposures change.
Another frustratingly familiar confounder is the problem of noncompliance. Studies of noncompliance have found rates as high as 20% to 50% in general populations and 60% to 80% in psychiatric patients.27 The fact that a patient's race might affect his or her chance of being a poor metabolizer by 10% to 20% pales in comparison to the fact that he is likely to take less than half of the prescribed medication. Spending more time with a patient or implementing psychosocial intervetions to improve compliance will probably be more cost-effective than spending $1000 on pharmacogenetic or pharmacometabonomic assays.
Race or ethnicity should not be irrelevant for psychiatrists. Both continue to be social variables of enormous significance, influencing the distribution of health risks and social resources and generating enormous disparities in wealth, disease rates, treatment, and mortality.28 A patient's racial or ethnic background might be relevant for understanding attitudes toward mental illness or willingness to start medications or engage in therapy, but these risks, resources, and attitudes are also influenced by socioeconomic status, education, religious beliefs, family background, and many other factors. The solution cannot be simple-minded racial profiling or cultural competence, in which all members of one group are treated in a standardized way. Instead, especially in psychiatry, we must practice individual profiling: the more we know about an individual, the better we can treat that patient.
What do I do in my own practice? I work in a setting of incredible diversity: the Psychiatric Emergency Service at Cambridge Hospital in Massachusetts. In recent weeks, I have treated patients from Boston, Cape Verde, Egypt, Brazil, Florida, India, Haiti, and countless other local and remote locations. Unlike Satel, I do not jump from a patient's race to a prediction about his drug response. Instead, I take a conservative but generalized approach: start low and go slow. This process will eventually find the right drug and dosage for every patient, without resorting to unreliable assumptions about race and ethnicity.
Does this increase the time it takes to find the optimal dose for each patient? Possibly. Is it overly cautious? Possibly. If my 42-year-old patient responded to 10 mg of fluoxetine, would I be more likely to suspect poor metabolism if he were black than if he were white? Possibly. If I really wanted to know, I could test the genotype directly. But with my empiric approach, I do not need to know or assume anything about race or genotype; I find this the most honest way to practice.
Dr Jones is an assistant professor of the history of science at the Massachusetts Institute of Technology, a lecturer in social medicine at Harvard Medical School, and an attending psychiatrist in the Psychiatric Emergency Service of Cambridge Hospital. He reports that he has no conflicts of interest concerning the subject matter of this article.
References1. Satel SL. I am a racial profiling doctor: illness isn't colorblind. So why is it taboo for doctors to take note of a patient's race? N Y Times Magazine. 2002, May 5:56-58.
2. Sankar P, Kahn J. BiDil: race medicine or race marketing? Health Aff (Millwood). 2005 Oct 11; [Epub ahead of print].
3. Jones DS, Perlis RH. Pharmacogenetics, race, and psychiatry: prospects and challenges. Harv Rev Psychiatry. 2006;14:92-108.
4. Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry. 2001;62(suppl 13):13-19.
5. Shields AE, Fortun M, Hammonds EM, et al. The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. Am Psychol. 2005;60:77-103.
6. Kevles DJ. In the Name of Eugenics: Genetics and the Uses of Human Heredity. Berkeley, Calif: University of California Press; 1985.
7. Reardon J. Race to the Finish: Identity and Governance in an Age of Genomics. Princeton, NJ: Princeton University Press; 2005.
8. Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure of human populations. Science. 2002;298:2381-2385.
9. Altshuler D, Clark AG. Genetics: harvesting medical information from the human family tree. Science. 2005;307:1052-1053.
10. Goldstein DB, Cavalleri GL. Genomics: understanding human diversity. Nature. 2005;437:1241-1242.
11. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
12. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006;38:68-74.
13. Sinha M, Larkin EK, Elston RC, Redline S. Self-reported race and genetic admixture. N Engl J Med. 2006;354:421-422.
14. Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science. 1968;161:72-73.
15. Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science. 1968;159:1479-1480.
16. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11: 215-219.
17. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:383-386.
18. Is Race "Real"? A web forum hosted by the Social Science Research Council. Available at: http://raceandgenomics.ssrc.org/. Accessed October 23, 2006.
19. Schwartz RS. Racial profiling in medical research. N Engl J Med. 2001;344:1392-1393.
20. Collins FS. What we do and don't know about "race," "ethnicity," genetics and health at the dawn of the genome era. Nat Genet. 2004;36(suppl 11):S13-S15.
21. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004;43:566-572.
22. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
23. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet. 2002;11:2517-2530.
24. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs. 2003;17:143-151.
25. Lin KM, Smith MW, Ortiz V. Culture and psychopharmacology. Psychiatry Clin North Am. 2001;24:523-538.
26. Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440:1073-1077.
27. Breen R, Thornhill JT. Noncompliance with medication for psychiatric disorders. CNS Drugs. 1998;9:457-471.
28. Duster T. Medicine: race and reification in science. Science. 2005;307:1050-1051.
29. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29:192-209.
30. Lin KM, Poland RE, Anderson D. Psychopharmacology, ethnicity, and culture. Transcultural Psychiatric Res Rev. 1995;32:3-40.
31. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-850.
32. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003;35:99-106.
33. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.